JP2018522567A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018522567A5 JP2018522567A5 JP2018506286A JP2018506286A JP2018522567A5 JP 2018522567 A5 JP2018522567 A5 JP 2018522567A5 JP 2018506286 A JP2018506286 A JP 2018506286A JP 2018506286 A JP2018506286 A JP 2018506286A JP 2018522567 A5 JP2018522567 A5 JP 2018522567A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- cell
- specific
- cells
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022069615A JP7566817B2 (ja) | 2015-08-07 | 2022-04-20 | 固形腫瘍を標的とする二重特異性ｃａｒ ｔ細胞 |
| JP2024172910A JP2025000906A (ja) | 2015-08-07 | 2024-10-02 | 固形腫瘍を標的とする二重特異性ｃａｒ ｔ細胞 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562202698P | 2015-08-07 | 2015-08-07 | |
| US62/202,698 | 2015-08-07 | ||
| PCT/US2016/045360 WO2017027291A1 (en) | 2015-08-07 | 2016-08-03 | Bispecific car t-cells for solid tumor targeting |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022069615A Division JP7566817B2 (ja) | 2015-08-07 | 2022-04-20 | 固形腫瘍を標的とする二重特異性ｃａｒ ｔ細胞 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018522567A JP2018522567A (ja) | 2018-08-16 |
| JP2018522567A5 true JP2018522567A5 (cg-RX-API-DMAC7.html) | 2019-09-12 |
| JP7162530B2 JP7162530B2 (ja) | 2022-10-28 |
Family
ID=57984403
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018506286A Active JP7162530B2 (ja) | 2015-08-07 | 2016-08-03 | 固形腫瘍を標的とする二重特異性ｃａｒ ｔ細胞 |
| JP2022069615A Active JP7566817B2 (ja) | 2015-08-07 | 2022-04-20 | 固形腫瘍を標的とする二重特異性ｃａｒ ｔ細胞 |
| JP2024172910A Pending JP2025000906A (ja) | 2015-08-07 | 2024-10-02 | 固形腫瘍を標的とする二重特異性ｃａｒ ｔ細胞 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022069615A Active JP7566817B2 (ja) | 2015-08-07 | 2022-04-20 | 固形腫瘍を標的とする二重特異性ｃａｒ ｔ細胞 |
| JP2024172910A Pending JP2025000906A (ja) | 2015-08-07 | 2024-10-02 | 固形腫瘍を標的とする二重特異性ｃａｒ ｔ細胞 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US11458167B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3331920A4 (cg-RX-API-DMAC7.html) |
| JP (3) | JP7162530B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN108174604B (cg-RX-API-DMAC7.html) |
| AU (2) | AU2016306209B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2994829A1 (cg-RX-API-DMAC7.html) |
| HK (1) | HK1256087A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2018001568A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2017027291A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (88)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ739448A (en) | 2014-04-10 | 2019-10-25 | Seattle Children’S Hospital Dba Seattle Children’S Res Institute | Transgene genetic tags and methods of use |
| RU2763795C2 (ru) | 2014-04-23 | 2022-01-11 | Джуно Терапьютикс, Инк. | Способы выделения, культивирования и генетической инженерии популяций клеток иммунной системы для адоптивной терапии |
| EP4400516A1 (en) | 2014-12-15 | 2024-07-17 | The Regents of the University of California | Bispecific or-gate chimeric antigen receptor responsive to cd19 and cd20 |
| WO2017027291A1 (en) * | 2015-08-07 | 2017-02-16 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Bispecific car t-cells for solid tumor targeting |
| EP3411393B1 (en) | 2016-02-05 | 2021-04-07 | City of Hope | Administration of engineered t cells for treatment of cancers in the central nervous system |
| US20200281973A1 (en) * | 2016-03-04 | 2020-09-10 | Novartis Ag | Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore |
| EP3494135A1 (en) | 2016-08-02 | 2019-06-12 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Monoclonal antibodies targeting glypican-2 (gpc2) and use thereof |
| CN110291200B (zh) | 2016-12-12 | 2024-05-14 | 西雅图儿童医院（Dba西雅图儿童研究所） | 对哺乳动物细胞中转基因表达的药剂配体诱导具有增大的灵敏度的嵌合转录因子变异体 |
| WO2019006468A1 (en) * | 2017-06-30 | 2019-01-03 | Memorial Sloan Kettering Cancer Center | COMPOSITIONS AND METHODS FOR ADOPTIVE CELL THERAPY |
| WO2019006465A1 (en) * | 2017-06-30 | 2019-01-03 | Memorial Sloan Kettering Cancer Center | COMPOSITIONS AND METHODS FOR ADOPTIVE CELL THERAPY AGAINST CANCER |
| EP3645708A4 (en) * | 2017-06-30 | 2021-06-23 | Memorial Sloan-Kettering Cancer Center | COMPOSITIONS AND METHODS OF ADOPTIVE CELL THERAPY FOR CANCER |
| CA3071624A1 (en) * | 2017-07-31 | 2019-02-07 | Lentigen Technology, Inc. | Compositions and methods for treating cancer with anti-cd19/cd20 immunotherapy |
| CN109423495A (zh) * | 2017-08-24 | 2019-03-05 | 上海恒润达生生物科技有限公司 | 一种双靶向嵌合抗原受体及其用途 |
| WO2019079486A1 (en) | 2017-10-18 | 2019-04-25 | Intrexon Corporation | POLYPEPTIDE COMPOSITIONS COMPRISING SPACERS |
| DK3704230T3 (da) | 2017-11-01 | 2025-01-02 | Juno Therapeutics Inc | Fremgangsmåde til generering af terapeutiske sammensætninger af modificerede celler |
| BR112020008638A2 (pt) * | 2017-11-01 | 2020-10-20 | Juno Therapeutics Inc | receptores de antígenos quiméricos específicos para antígenos de maturação de células b (bcma) |
| BR112020008812A2 (pt) | 2017-11-06 | 2020-10-27 | Juno Therapeutics Inc | combinação de terapia celular e um inibidor de gama secretase |
| WO2019094482A1 (en) * | 2017-11-10 | 2019-05-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric antigen receptors targeting tumor antigens |
| US12139522B2 (en) | 2017-12-05 | 2024-11-12 | The Medical Research Infrastructure And Heal Serviced Fund Of The Tel Aviv Medecal Center | T-cells comprising two different chimeric antigen receptors and uses thereof |
| IL274806B2 (en) | 2017-12-05 | 2025-04-01 | Medical Res Infrastructure & Health Services Fund Tel Aviv Medical Ct | T cells containing chimeric receptors for CD138 and CD38 antigens and their use |
| CN109970864A (zh) * | 2017-12-28 | 2019-07-05 | 上海细胞治疗研究院 | 一种双向激活共刺激分子受体及其用途 |
| CN109970867B (zh) * | 2017-12-28 | 2022-10-18 | 上海细胞治疗研究院 | 一种cd40双向激活共刺激分子受体及其用途 |
| CN109970866B (zh) * | 2017-12-28 | 2022-10-04 | 上海细胞治疗研究院 | 一种cd28双向激活共刺激分子受体及其用途 |
| CN111867619A (zh) | 2018-01-03 | 2020-10-30 | 曲生物制品公司 | 过继性细胞治疗的先天寻靶 |
| EP3544618A4 (en) * | 2018-01-11 | 2020-02-12 | Innovative Cellular Therapeutics Inc. | MODIFIED CELL EXPANSION AND USES THEREOF |
| US10561686B2 (en) | 2018-01-12 | 2020-02-18 | Innovative Cellular Therapeutics CO., LTD. | Modified cell expansion and uses thereof |
| US10869888B2 (en) | 2018-04-17 | 2020-12-22 | Innovative Cellular Therapeutics CO., LTD. | Modified cell expansion and uses thereof |
| GB201807862D0 (en) * | 2018-05-15 | 2018-06-27 | Ucl Business Plc | Chimeric antigen receptor |
| US12448426B2 (en) * | 2018-05-17 | 2025-10-21 | St. Jude Children's Research Hospital, Inc. | Chimeric antigen receptors with MYD88 and CD40 costimulatory domains |
| CN112399860B (zh) | 2018-06-06 | 2024-08-16 | 麻省理工学院 | 用于在真核细胞中翻译的环状rna |
| CA3100282A1 (en) | 2018-06-19 | 2019-12-26 | Nantcell, Inc. | Hiv treatment compositions and methods |
| JP7447388B2 (ja) * | 2018-07-13 | 2024-03-12 | ナンジン レジェンド バイオテック カンパニー，リミテッド | 感染性疾患の治療のための共受容体システム |
| CN108948211B (zh) | 2018-07-24 | 2021-08-20 | 北京美康基免生物科技有限公司 | 一种基于靶向gd2的嵌合抗原受体及其应用 |
| US20210290676A1 (en) * | 2018-07-30 | 2021-09-23 | University Of Southern California | Improving the efficacy and safety of adoptive cellular therapies |
| WO2020033430A1 (en) * | 2018-08-08 | 2020-02-13 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | High affinity monoclonal antibodies targeting glypican-2 and uses thereof |
| CN110845621A (zh) * | 2018-08-21 | 2020-02-28 | 上海恒润达生生物科技有限公司 | 一种靶向egfr和cd19双靶点的嵌合抗原受体方法 |
| CA3110926A1 (en) * | 2018-08-28 | 2020-03-05 | Pharos Vaccine Inc. | Improved lentiviral vector |
| US12240915B2 (en) | 2018-08-30 | 2025-03-04 | Innovative Cellular Therapeutics Holdings, Ltd. | Chimeric antigen receptor cells for treating solid tumor |
| CN109503716B (zh) * | 2018-10-08 | 2021-04-27 | 浙江生研生物科技有限公司 | 一种双特异性嵌合抗原受体分子及其在肿瘤治疗上的应用 |
| CN109266618B (zh) * | 2018-10-18 | 2021-04-23 | 赛元生物科技(杭州)有限公司 | 能够靶向肿瘤细胞的巨噬细胞及其制备方法 |
| BR112021007334A2 (pt) * | 2018-10-19 | 2021-08-03 | Cartexell Inc. | anticorpo anti-l1cam ou fragmento de ligação ao antígeno do mesmo, e receptor de antígeno quimérico compreendendo o mesmo |
| SG11202104188VA (en) | 2018-11-01 | 2021-05-28 | Juno Therapeutics Inc | Methods for treatment using chimeric antigen receptors specific for b-cell maturation antigen |
| JP2022512968A (ja) | 2018-11-01 | 2022-02-07 | グレイセル・バイオテクノロジーズ（シャンハイ）カンパニー・リミテッド | Ｔ細胞操作のための組成物および方法 |
| CN109400710A (zh) * | 2018-11-02 | 2019-03-01 | 山西大医院（山西医学科学院） | 一种靶向kif20a阳性胰腺癌双特异性抗体及其制备方法和应用 |
| KR20210093977A (ko) * | 2018-11-19 | 2021-07-28 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | 자살 유전자 |
| US10918667B2 (en) | 2018-11-20 | 2021-02-16 | Innovative Cellular Therapeutics CO., LTD. | Modified cell expressing therapeutic agent and uses thereof |
| EP3894436A4 (en) * | 2018-12-14 | 2022-10-12 | 2seventy bio, Inc. | Dimerizing agent regulated immunoreceptor complexes |
| CN111748017A (zh) * | 2019-03-26 | 2020-10-09 | 上海瑞可新生物科技有限公司 | 一种抗原多肽及其表达载体、组合药物、试剂盒和应用 |
| AU2020272074A1 (en) * | 2019-04-12 | 2021-11-25 | The Trustees Of The University Of Pennsylvania | Compositions and Methods Comprising a High Affinity Chimeric Antigen Receptor (CAR) with Cross-Reactivity to Clinically-Relevant EGFR Mutated Proteins |
| SG11202111130SA (en) | 2019-04-30 | 2021-11-29 | Senti Biosciences Inc | Chimeric receptors and methods of use thereof |
| BR112021021608A2 (pt) * | 2019-04-30 | 2021-12-21 | Atara Biotherapeutics Inc | Células car-t direcionadas a cd19 específicas para antígeno |
| JP2022531439A (ja) * | 2019-05-07 | 2022-07-06 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | ヒンジドメインを介したポリペプチド及びキメラ抗原受容体の増強 |
| EP3965897A4 (en) * | 2019-05-07 | 2023-01-04 | The Board of Trustees of the Leland Stanford Junior University | CHEMERA ANTIGEN RECEPTORS TARGETING GLYPICAN-2 |
| CA3139032A1 (en) | 2019-05-22 | 2020-11-26 | Robert Alexander WESSELHOEFT | Circular rna compositions and methods |
| US20200384029A1 (en) * | 2019-06-07 | 2020-12-10 | The Trustees Of The University Of Pennsylvania | Dual car expressing t cells individually linked to cd28 and 4-1bb |
| PH12022550102A1 (en) * | 2019-07-24 | 2022-11-21 | Regeneron Pharma | Chimeric antigen receptors with mage-a4 specificity and uses thereof |
| CA3146298A1 (en) * | 2019-07-30 | 2021-02-04 | University Health Network | T cell receptors and methods of use thereof |
| US20210128617A1 (en) * | 2019-08-27 | 2021-05-06 | The Trustees Of The University Of Pennsylvania | SYNTHETIC CARS TO TREAT IL13R-alpha-2 POSITIVE HUMAN AND CANINE TUMORS |
| US12139544B2 (en) | 2019-11-08 | 2024-11-12 | Mayo Foundation For Medical Education And Research | EphA3 directed CAR-T cells for treatment of tumors |
| US20220411535A1 (en) * | 2019-11-26 | 2022-12-29 | University Of Utah Research Foundation | Compositions and methods for upregulating hla class i on tumor cells |
| EP4289951A3 (en) | 2019-12-04 | 2024-03-13 | Orna Therapeutics, Inc. | Circular rna compositions and methods |
| CN113106067B (zh) * | 2020-01-10 | 2024-06-21 | 南京大学 | 一种嵌合抗原受体-单核/巨噬细胞(car-m)的构建及其应用 |
| US12076343B2 (en) | 2020-02-19 | 2024-09-03 | Innovative Cellular Therapeutics Holdings, Ltd. | Engineered safety in cell therapy |
| CN113402612A (zh) | 2020-03-17 | 2021-09-17 | 西比曼生物科技（香港）有限公司 | 靶向cd19和cd20的联合嵌合抗原受体及其应用 |
| EP3892720A1 (en) * | 2020-04-06 | 2021-10-13 | Innovative Cellular Therapeutics Holdings, Ltd. | Presenting cell and use thereof in cell therapy |
| US20230201258A1 (en) * | 2020-04-23 | 2023-06-29 | Innovative Cellular Therapeutics Holdings, Ltd. | Polyspecific Binding Molecules and their use in Cell Therapy |
| EP4146697A1 (en) * | 2020-05-05 | 2023-03-15 | Regeneron Pharmaceuticals, Inc. | Car comprising cd28 zeta and cd3 zeta |
| US12043654B2 (en) | 2020-06-02 | 2024-07-23 | Innovative Cellular Therapeutics Holdings, Ltd. | Anti-GCC antibody and CAR thereof for treating digestive system cancer |
| CN115803038A (zh) * | 2020-06-08 | 2023-03-14 | 西雅图儿童医院（Dba西雅图儿童研究所） | 抗cd171嵌合抗原受体 |
| WO2022036495A1 (en) | 2020-08-17 | 2022-02-24 | Utc Therapeutics Inc. | Lymphocytes-antigen presenting cells co-stimulators and uses thereof |
| JP2023545681A (ja) * | 2020-09-30 | 2023-10-31 | インスティテュート オブ ズーオロジー、チャイニーズ アカデミー オブ サイエンシーズ | Ｅｇｆｒを標的とするキメラ抗原受容体 |
| WO2022125387A1 (en) * | 2020-12-08 | 2022-06-16 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Anti-egfr chimeric antigen receptors |
| CN116600819A (zh) * | 2020-12-09 | 2023-08-15 | 艾弗依姆恩治疗公司 | 靶向epcam和icam-1的双嵌合抗原受体 |
| CN114685683B (zh) * | 2020-12-31 | 2025-07-08 | 博生吉医药科技(苏州)有限公司 | 靶向gd2的car-t细胞及其制备和应用 |
| US12144827B2 (en) | 2021-02-25 | 2024-11-19 | Lyell Immunopharma, Inc. | ROR1 targeting chimeric antigen receptor |
| JP2024532305A (ja) * | 2021-08-24 | 2024-09-05 | 賽斯尓▲チン▼生物技術（上海）有限公司 | 細胞を修飾する方法 |
| JP2025508961A (ja) * | 2022-03-03 | 2025-04-10 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | 抗ＣＤ１９および抗ＣＤ７９ｂキメラ抗原受容体ならびにその使用方法 |
| CN114573711A (zh) * | 2022-03-04 | 2022-06-03 | 陕西师范大学 | 一种TanCAR的构建及其应用 |
| CN114605560B (zh) * | 2022-03-30 | 2024-02-20 | 江苏蒙彼利生物科技有限公司 | 一种car-nk细胞及其制备方法与应用 |
| US12297285B2 (en) | 2022-06-24 | 2025-05-13 | Orna Therapeutics, Inc. | Circular RNA encoding chimeric antigen receptors targeting BCMA |
| WO2024026505A2 (en) * | 2022-07-29 | 2024-02-01 | Amit Patel | Disruption of telocyte activity |
| WO2024059733A2 (en) * | 2022-09-14 | 2024-03-21 | Fred Hutchinson Cancer Center | Chimeric antigen receptors binding nectin-4 |
| WO2024097911A1 (en) * | 2022-11-02 | 2024-05-10 | Fate Therapeutics, Inc. | Off-the-shelf therapeutic cells with multiplex genomic engineering for targeting gprc5d |
| CN118240777A (zh) * | 2022-12-24 | 2024-06-25 | 深圳市菲鹏生物治疗股份有限公司 | 细胞组合物及其应用和药物 |
| EP4626447A1 (en) | 2023-03-31 | 2025-10-08 | AbelZeta Inc. | Bispecific chimeric antigen receptors targeting cd20 and bcma |
| WO2025029484A1 (en) * | 2023-07-31 | 2025-02-06 | Bio4T2, Llc | Methods of blood cell-mediated in vivo car cell expansion and engraftment |
| CN117338914B (zh) * | 2023-10-27 | 2024-09-06 | 中山市珈钰生物医药有限公司 | 一种同种异体树突细胞肿瘤疫苗及其制备方法和应用 |
| WO2025113635A1 (zh) * | 2023-12-01 | 2025-06-05 | 上海祥耀生物科技有限责任公司 | 抗cd84抗体及其用途 |
Family Cites Families (95)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE159548T1 (de) | 1990-11-13 | 1997-11-15 | Immunex Corp | Bifunktionelle wählbare fusionsgene |
| US20020111474A1 (en) | 1990-12-14 | 2002-08-15 | Capon Daniel J. | Chimeric chains for receptor-associated signal transduction pathways |
| WO1994000143A1 (en) | 1992-06-01 | 1994-01-06 | New England Medical Center Hospitals, Inc. | Blocking intercellular interactions with cd43 chimeric molecules |
| US5827642A (en) | 1994-08-31 | 1998-10-27 | Fred Hutchinson Cancer Research Center | Rapid expansion method ("REM") for in vitro propagation of T lymphocytes |
| US5783186A (en) | 1995-12-05 | 1998-07-21 | Amgen Inc. | Antibody-induced apoptosis |
| US6660257B1 (en) | 1996-10-25 | 2003-12-09 | Pharmacia Corporation | Circular permuteins of flt3 ligand |
| US6410319B1 (en) | 1998-10-20 | 2002-06-25 | City Of Hope | CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies |
| GB0015119D0 (en) | 2000-06-20 | 2000-08-09 | Angeletti P Ist Richerche Bio | Methods and means for regulation of gene expression |
| KR100545945B1 (ko) | 2000-07-03 | 2006-01-25 | 갈라 디자인, 인크. | 발현 벡터 |
| JP5312721B2 (ja) | 2000-11-07 | 2013-10-09 | シティ・オブ・ホープ | Ｃｄ１９特異的再指向免疫細胞 |
| HUP0303428A2 (hu) | 2001-03-07 | 2004-01-28 | Merck Patent Gmbh. | Expressziós eljárás hibrid izotípusú antitestcsoportot tartalmazó fehérjékhez |
| US7070995B2 (en) * | 2001-04-11 | 2006-07-04 | City Of Hope | CE7-specific redirected immune cells |
| US20090257994A1 (en) | 2001-04-30 | 2009-10-15 | City Of Hope | Chimeric immunoreceptor useful in treating human cancers |
| WO2002097099A1 (en) | 2001-05-29 | 2002-12-05 | Valentis, Inc. | Regulated expression of ghrh |
| US20050004017A1 (en) | 2001-09-18 | 2005-01-06 | Yuval Reiss | Methods and compositions for treating hcap associated diseases |
| US20030148982A1 (en) | 2001-11-13 | 2003-08-07 | Brenner Malcolm K. | Bi-spcific chimeric T cells |
| CA2481509A1 (en) | 2002-04-11 | 2003-10-23 | Suzanna Tatarewicz | Her-2 receptor tyrosine kinase molecules and uses thereof |
| US20040115814A1 (en) | 2002-09-30 | 2004-06-17 | Protein Design Labs, Inc. | Efficient generation of stable expression cell lines through the use of scorable homeostatic reporter genes |
| US20040158329A1 (en) | 2003-02-10 | 2004-08-12 | Waldemar Link (Gmbh & Co.) | Hip joint prosthesis with shaft inserted into femur |
| EP2100619B1 (en) | 2003-02-20 | 2014-02-12 | Seattle Genetics, Inc. | Anti-CD70 antibody-drug conjugates and their use for the treatment of immune disorders |
| US20050129671A1 (en) | 2003-03-11 | 2005-06-16 | City Of Hope | Mammalian antigen-presenting T cells and bi-specific T cells |
| WO2004092338A2 (en) | 2003-04-11 | 2004-10-28 | Diadexus, Inc. | Compositions, splice variants and methods relating to cancer specific genes and proteins |
| WO2005017102A2 (en) | 2003-05-30 | 2005-02-24 | Diadexus, Inc. | Compositions, splice variants and methods relating to ovarian specific nucleic acids and proteins |
| CA2532460C (en) | 2003-07-21 | 2012-04-24 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Synthetic gene encoding human epidermal growth factor 2/neu antigen and uses thereof |
| US20070087346A1 (en) | 2003-10-24 | 2007-04-19 | Gennaro Ciliberto | Orthogonal gene switches |
| US20130266551A1 (en) | 2003-11-05 | 2013-10-10 | St. Jude Children's Research Hospital, Inc. | Chimeric receptors with 4-1bb stimulatory signaling domain |
| US8071364B2 (en) | 2003-12-24 | 2011-12-06 | Transgenrx, Inc. | Gene therapy using transposon-based vectors |
| US20090098142A1 (en) | 2004-06-09 | 2009-04-16 | Kasaian Marion T | Methods and compositions for treating and monitoring treatment of IL-13-associated disorders |
| US7910101B2 (en) | 2004-10-25 | 2011-03-22 | Centocor, Inc. | Melanocortin receptor binding mimetibodies, compositions, methods and uses |
| AU2006327175A1 (en) | 2005-12-21 | 2007-06-28 | Medimmune, Llc | Epha2 bite molecules and uses thereof |
| AU2007254508B2 (en) | 2006-05-22 | 2012-03-22 | Hiprocell, Llc | Protein production using eukaryotic cell lines |
| WO2008012237A1 (en) | 2006-07-24 | 2008-01-31 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa | Multi-antigen construct and uses thereof |
| US7709253B2 (en) | 2006-08-04 | 2010-05-04 | The Board Of Trustees Of The Leland Stanford Junior University | Ligand-regulable transactivation systems, methods of use thereof, methods of detecting estrogen receptor ligands, and methods of differentiating estrogen receptor ligand agonists and antagonists |
| US20100183516A1 (en) | 2007-07-25 | 2010-07-22 | Markus Ribbert | Self coupling recombinant antibody fusion proteins |
| WO2009091826A2 (en) | 2008-01-14 | 2009-07-23 | The Board Of Regents Of The University Of Texas System | Compositions and methods related to a human cd19-specific chimeric antigen receptor (h-car) |
| US8450112B2 (en) | 2008-04-09 | 2013-05-28 | Maxcyte, Inc. | Engineering and delivery of therapeutic compositions of freshly isolated cells |
| JP2012501180A (ja) | 2008-08-26 | 2012-01-19 | シティ・オブ・ホープ | Ｔ細胞の抗腫瘍エフェクター機能増進のための方法および組成物 |
| US8829173B2 (en) | 2008-09-26 | 2014-09-09 | Tocagen Inc. | Recombinant vectors |
| WO2010036986A2 (en) | 2008-09-26 | 2010-04-01 | Tocagen Inc. | Recombinant vectors |
| US8329882B2 (en) | 2009-02-18 | 2012-12-11 | California Institute Of Technology | Genetic control of mammalian cells with synthetic RNA regulatory systems |
| EP2438443A4 (en) | 2009-06-02 | 2012-07-25 | Targeted Molecular Diagnostics Llc | METHOD FOR DETECTING AND QUANTIFYING THE P95 COMPONENT OF HER2 / NEU (ERBB2) |
| US8075895B2 (en) | 2009-09-22 | 2011-12-13 | Janssen Pharmaceutica N.V. | Identification of antigenic peptides from multiple myeloma cells |
| EP4049674A1 (en) | 2009-11-03 | 2022-08-31 | City of Hope | Truncated epidermal growth factor receptor (egfrt) for transduced t cell selection |
| JP5285678B2 (ja) | 2010-06-18 | 2013-09-11 | 株式会社エヌ・ティ・ティ・ドコモ | 移動通信方法及びコアネットワーク装置 |
| PT3012268T (pt) | 2010-09-08 | 2018-01-31 | Chemotherapeutisches Forschungsinstitut Georg Speyer Haus | Recetores de antigénio quimérico com uma região de charneira otimizada |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| US9402865B2 (en) | 2011-01-18 | 2016-08-02 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treating cancer |
| BR112013024395B1 (pt) | 2011-03-23 | 2021-10-26 | Fred Hutchinson Cancer Research Center | Composições adotivas de imunoterapia celular e método para fabricação da dita composição |
| KR102028340B1 (ko) | 2011-04-13 | 2019-10-04 | 이뮤니쿰 에이비 | 항원-특이적 t 세포의 증식 방법 |
| DK3489366T3 (da) | 2011-06-01 | 2020-02-24 | Prec Biosciences Inc | Fremgangsmåder og produkter til produktion af manipulerede mammale cellelinier med forstærkede transgener |
| MX354663B (es) | 2011-06-22 | 2018-03-14 | Hoffmann La Roche | Eliminación de células diana por parte de células t citotóxicas específicas de virus utilizando complejos que comprenden mhc de clase i. |
| DE102011118018B4 (de) | 2011-10-25 | 2017-10-26 | Plasmidfactory Gmbh & Co. Kg | Minicircles mit Transpositionskassetten und ihre Verwendung zur Transformation von Zellen |
| WO2013074916A1 (en) | 2011-11-18 | 2013-05-23 | Board Of Regents, The University Of Texas System | Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla |
| EP3594245A1 (en) * | 2012-02-13 | 2020-01-15 | Seattle Children's Hospital d/b/a Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
| ITRM20120058A1 (it) | 2012-02-20 | 2013-08-21 | Pisanelli Giovanni Codacci | Famiglia di molecole a base di zuccheri ad uso terapeutico e relativo procedimento di produzione |
| SG11201404769UA (en) | 2012-02-22 | 2014-11-27 | Univ Pennsylvania | Use of icos-based cars to enhance antitumor activity and car persistence |
| EP2836239A1 (en) | 2012-04-11 | 2015-02-18 | The United States of America, as Represented By the Secretary, Department of Health and Human Services | Chimeric antigen receptors targeting b-cell maturation antigen |
| US20130280220A1 (en) | 2012-04-20 | 2013-10-24 | Nabil Ahmed | Chimeric antigen receptor for bispecific activation and targeting of t lymphocytes |
| US9540657B2 (en) | 2012-05-25 | 2017-01-10 | California Institute Of Technology | Expression of secreted and cell-surface polypeptides |
| AU2013267350A1 (en) | 2012-05-30 | 2015-01-29 | Baylor College Of Medicine | Supercoiled MiniVectors as a tool for DNA repair, alteration and replacement |
| EP2669378A1 (en) | 2012-05-31 | 2013-12-04 | Helmut Hanenberg | Cytochrome P450 suicide gene system |
| US9792559B2 (en) | 2012-06-01 | 2017-10-17 | Nec Corporation | Switching system, line card, switch card, FDB learning method, FDB learning arbitration method and program |
| SMT202100005T1 (it) * | 2012-08-20 | 2021-05-07 | Hutchinson Fred Cancer Res | Metodo e composizioni per immunoterapia cellulare |
| WO2014039044A1 (en) | 2012-09-06 | 2014-03-13 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of producing t memory stem cell populations |
| EP2903637B1 (en) | 2012-10-02 | 2019-06-12 | Memorial Sloan-Kettering Cancer Center | Compositions and methods for immunotherapy |
| US10117896B2 (en) * | 2012-10-05 | 2018-11-06 | The Trustees Of The University Of Pennsylvania | Use of a trans-signaling approach in chimeric antigen receptors |
| WO2014099671A1 (en) | 2012-12-20 | 2014-06-26 | Bluebird Bio, Inc. | Chimeric antigen receptors and immune cells targeting b cell malignancies |
| CN105339498A (zh) | 2013-03-07 | 2016-02-17 | 贝勒医学院 | 癌症中靶向cd138 |
| EP2777711A1 (en) | 2013-03-11 | 2014-09-17 | Icon Genetics GmbH | Her2/Neu cancer vaccine |
| UY35468A (es) | 2013-03-16 | 2014-10-31 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19 |
| SG11201509609SA (en) | 2013-05-24 | 2015-12-30 | Univ Texas | Chimeric antigen receptor-targeting monoclonal antibodies |
| MX389160B (es) * | 2013-10-31 | 2025-03-20 | Hutchinson Fred Cancer Res | Células no t efectoras y madre/progenitoras hematopoyéticas modificadas y usos de estas. |
| EP3071221A1 (en) * | 2013-11-21 | 2016-09-28 | UCL Business Plc. | Cell |
| JP2017504601A (ja) * | 2013-12-20 | 2017-02-09 | セレクティスＣｅｌｌｅｃｔｉｓ | 免疫療法のためにマルチインプットシグナル感受性ｔ細胞を操作する方法 |
| EP3626748A1 (en) * | 2014-01-13 | 2020-03-25 | Stephen J. Forman | Chimeric antigen receptors (cars) having mutations in the fc spacer region and methods for their use |
| RU2021123419A (ru) | 2014-02-14 | 2021-10-22 | Борд Оф Риджентс, Дзе Юниверсити Оф Техас Систем | Химерные антигенные рецепторы и способы их получения |
| JP2017513818A (ja) | 2014-03-15 | 2017-06-01 | ノバルティス アーゲー | キメラ抗原受容体を使用する癌の処置 |
| NZ739448A (en) | 2014-04-10 | 2019-10-25 | Seattle Children’S Hospital Dba Seattle Children’S Res Institute | Transgene genetic tags and methods of use |
| DE112014006656B4 (de) | 2014-05-14 | 2018-05-17 | Carsgen Therapeutics Limited | Nukleinsäure zur Kodierung eines chimären Antigen-Rezeptor-Proteins und T-Lymphozyt zur Expression eines chimären Antigen-Rezeptor-Proteins |
| SG11201609960QA (en) | 2014-06-02 | 2016-12-29 | Us Health | Chimeric antigen receptors targeting cd-19 |
| TWI751102B (zh) | 2014-08-28 | 2022-01-01 | 美商奇諾治療有限公司 | 對ｃｄ１９具專一性之抗體及嵌合抗原受體 |
| MX389823B (es) | 2014-10-27 | 2025-03-20 | Fred Hutchinson Cancer Center | Composiciones y metodos para reforzar la eficacia de inmunoterapia celular adoptiva. |
| GB201503742D0 (en) | 2015-03-05 | 2015-04-22 | Ucl Business Plc | Chimeric antigen receptor |
| CN114634943A (zh) | 2015-05-18 | 2022-06-17 | T细胞受体治疗公司 | 使用融合蛋白对tcr重编程的组合物和方法 |
| KR102526538B1 (ko) | 2015-06-10 | 2023-04-28 | 이뮤너티바이오, 인크. | 암을 치료하기 위한 변형된 nk-92 세포 |
| US10639329B2 (en) | 2015-06-12 | 2020-05-05 | Lentigen Technology, Inc. | Method to treat cancer with engineered T-cells |
| WO2017027291A1 (en) | 2015-08-07 | 2017-02-16 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Bispecific car t-cells for solid tumor targeting |
| EP3411393B1 (en) | 2016-02-05 | 2021-04-07 | City of Hope | Administration of engineered t cells for treatment of cancers in the central nervous system |
| CN109415409B (zh) | 2016-04-01 | 2022-03-15 | 亘喜生物科技（上海）有限公司 | Flag标记的cd19-car-t细胞 |
| TWI779479B (zh) | 2016-09-28 | 2022-10-01 | 美商凱特製藥公司 | 抗原結合分子類和使用彼等之方法 |
| ES2811500T3 (es) | 2016-10-04 | 2021-03-12 | Prec Biosciences Inc | Dominios coestimuladores para su uso en células genéticamente modificadas |
| CN110291200B (zh) | 2016-12-12 | 2024-05-14 | 西雅图儿童医院（Dba西雅图儿童研究所） | 对哺乳动物细胞中转基因表达的药剂配体诱导具有增大的灵敏度的嵌合转录因子变异体 |
| JOP20180042A1 (ar) | 2017-04-24 | 2019-01-30 | Kite Pharma Inc | نطاقات ربط مولد ضد متوافقة مع البشر وطرق الاستخدام |
| US10869888B2 (en) | 2018-04-17 | 2020-12-22 | Innovative Cellular Therapeutics CO., LTD. | Modified cell expansion and uses thereof |
| US11104732B2 (en) | 2019-04-24 | 2021-08-31 | Innovative Cellular Therapeutics Holdings, Ltd. | Reducing immune inhibition induced by SIGLEC-15 |
-
2016
- 2016-08-03 WO PCT/US2016/045360 patent/WO2017027291A1/en not_active Ceased
- 2016-08-03 HK HK18115149.8A patent/HK1256087A1/zh unknown
- 2016-08-03 AU AU2016306209A patent/AU2016306209B2/en active Active
- 2016-08-03 JP JP2018506286A patent/JP7162530B2/ja active Active
- 2016-08-03 MX MX2018001568A patent/MX2018001568A/es unknown
- 2016-08-03 US US15/750,708 patent/US11458167B2/en active Active
- 2016-08-03 CN CN201680058143.5A patent/CN108174604B/zh active Active
- 2016-08-03 EP EP16835650.9A patent/EP3331920A4/en active Pending
- 2016-08-03 CA CA2994829A patent/CA2994829A1/en active Pending
-
2020
- 2020-11-03 US US17/088,005 patent/US11123369B2/en active Active
-
2022
- 2022-04-20 JP JP2022069615A patent/JP7566817B2/ja active Active
- 2022-09-12 US US17/931,258 patent/US20230130938A1/en active Pending
-
2023
- 2023-10-05 AU AU2023241321A patent/AU2023241321A1/en active Pending
-
2024
- 2024-10-02 JP JP2024172910A patent/JP2025000906A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018522567A5 (cg-RX-API-DMAC7.html) | ||
| US11123369B2 (en) | Bispecific CAR T-cells for solid tumor targeting | |
| JP7527049B2 (ja) | Ｃａｒ発現ベクター及びｃａｒ発現ｔ細胞 | |
| JP7267321B2 (ja) | 改善された特異性を有する改変型ｔリンパ球 | |
| He et al. | Targeting cancers through TCR-peptide/MHC interactions | |
| JP7221213B2 (ja) | 多官能性タンパク質 | |
| ES2732067T3 (es) | Receptor de antígeno quimérico (CAR) que contiene un dominio de unión a CD19 | |
| ES2681948T3 (es) | Células de acoplamiento para inmunoterapia | |
| ES2786263T3 (es) | Mejora de la actividad de los CAR de linfocitos T mediante la introducción conjunta de un anticuerpo biespecífico | |
| ES2833162T5 (es) | Receptor de antígeno quimérico y su uso | |
| Leisegang et al. | T-Cell Receptor Gene–Modified T Cells with Shared Renal Cell Carcinoma Specificity for Adoptive T-Cell Therapy | |
| US11890302B2 (en) | Gamma delta CAR-T cells comprising Fc gamma intracellular signaling domains | |
| WO2022033537A1 (zh) | 工程化免疫细胞及其用途 | |
| Essand et al. | Genetically engineered T cells for the treatment of cancer | |
| JP2015509717A (ja) | 抗腫瘍活性およびｃａｒ存続性を強化するためのｉｃｏｓベースのｃａｒの使用 | |
| JP2024054286A (ja) | 操作された細胞、ｔ細胞免疫調節抗体、およびそれらの使用方法 | |
| US20250002855A1 (en) | Methods for expanding t cells for the treatment of cancer and related malignancies | |
| Golubovskaya | CAR-T cells targeting immune checkpoint pathway players | |
| CN115232797A (zh) | 工程化免疫细胞及其用途 | |
| WO2023051361A1 (zh) | 工程化免疫细胞及其用途 | |
| Yu et al. | CAR NK cell therapy for solid tumors: Potential and challenges | |
| WO2023035947A1 (zh) | 工程化免疫细胞及其用途 | |
| Kebriaei et al. | CARs: driving T-cell specificity to enhance anti-tumor immunity | |
| US20250332195A1 (en) | Chimeric antigen receptor, cell expressing said receptor, pharmaceutical composition including said cell, method for producing said cell, and polynucleotide or vector including nucleotide sequence encoding said chimeric antigen receptor | |
| CN116103239A (zh) | 工程化免疫细胞及其用途 |